[{"indications": "Indications\u00a0motion sickness;\r\nhypersalivation associated with clozapine therapy; premedication (section 15.1.3); excessive respiratory secretions (see Prescribing in Palliative\r\nCare)", "name": "HYOSCINE HYDROBROMIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.6 Drugs used in nausea and vertigo", "Hyoscine", "HYOSCINE HYDROBROMIDE"], "cautions": "Cautions\u00a0section 1.2; also epilepsy", "side-effects": "Side-effects\u00a0section 1.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200878.htm", "doses": ["Motion sickness, by mouth, adult and child over\r\n10 years, 150\u2013300\u00a0micrograms up to 30 minutes before start of journey\r\nrepeated every 6 hours if required; max. 900\u00a0micrograms daily; child 3\u20134 years 75\u00a0micrograms up to 30 minutes before\r\nstart of journey repeated after 6 hours if required, max. 150\u00a0micrograms\r\ndaily; 4\u201310 years 75\u2013150\u00a0micrograms up to 30 minutes before start\r\nof journey repeated every 6 hours if required; max. 450\u00a0micrograms\r\ndaily", "Hypersalivation associated with clozapine therapy [unlicensed\r\nindication], by mouth, 300\u00a0micrograms up to 3 times\r\ndaily; max. 900\u00a0micrograms daily; child under 18 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0section 15.1.3"}, {"indications": "Indications\u00a0premedication, motion sickness, hypersalivation\r\nassociated with clozapine therapy (section 4.6); excessive respiratory secretions\r\n(see Prescribing in Palliative\r\nCare)", "name": "HYOSCINE HYDROBROMIDE - ANTIMUSCARINIC DRUGS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "15 Anaesthesia", "15.1 General anaesthesia", "15.1.3 Antimuscarinic drugs"], "cautions": "Cautions\u00a0see notes in section 1.2 and notes above; also epilepsy", "side-effects": "Side-effects\u00a0see notes in section 1.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6591.htm", "doses": ["Premedication, by subcutaneous or intramuscular injection, 200\u2013600\u00a0micrograms 30\u201360\u00a0minutes\r\nbefore induction of anaesthesia; child 15\u00a0micrograms/kg"], "pregnancy": "Pregnancy\u00a0use only if potential benefit outweighs risk; injection\r\nmay depress neonatal respiration"}, {"indications": "Indications\u00a0motion sickness;\r\nhypersalivation associated with clozapine therapy; premedication (section 15.1.3); excessive respiratory secretions (see Prescribing in Palliative\r\nCare)", "name": "HYOSCINE HYDROBROMIDE Patches", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.6 Drugs used in nausea and vertigo", "Hyoscine", "HYOSCINE HYDROBROMIDE", "Patches"], "cautions": "Cautions\u00a0section 1.2; also epilepsy", "side-effects": "Side-effects\u00a0section 1.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3452.htm", "doses": ["Motion sickness, by mouth, adult and child over\r\n10 years, 150\u2013300\u00a0micrograms up to 30 minutes before start of journey\r\nrepeated every 6 hours if required; max. 900\u00a0micrograms daily; child 3\u20134 years 75\u00a0micrograms up to 30 minutes before\r\nstart of journey repeated after 6 hours if required, max. 150\u00a0micrograms\r\ndaily; 4\u201310 years 75\u2013150\u00a0micrograms up to 30 minutes before start\r\nof journey repeated every 6 hours if required; max. 450\u00a0micrograms\r\ndaily", "Hypersalivation associated with clozapine therapy [unlicensed\r\nindication], by mouth, 300\u00a0micrograms up to 3 times\r\ndaily; max. 900\u00a0micrograms daily; child under 18 years see BNF for Children", "Name[Scopoderm TTS\u00ae (Novartis Consumer Health) ] Patch, self-adhesive, pink, releasing\r\nhyoscine approx. 1\u00a0mg/72 hours when in contact with skin, net price\r\n2 = \u00a34.30. \r\n    Label:\r\n    19, counselling, see belowDose\u00a0 motion sickness prevention, apply 1 patch to hairless\r\narea of skin behind ear 5\u20136 hours before journey; replace if necessary\r\nafter 72 hours, siting replacement patch behind other ear; child under 10 years not recommendedCounselling\u00a0Explain accompanying instructions\r\nto patient and in particular emphasise advice to wash hands after\r\nhandling and to wash application site after removing, and to use one\r\npatch at a time"], "pregnancy": "Pregnancy\u00a0section 15.1.3"}, {"indications": "Indications\u00a0motion sickness;\r\nhypersalivation associated with clozapine therapy; premedication (section 15.1.3); excessive respiratory secretions (see Prescribing in Palliative\r\nCare)", "name": "HYOSCINE HYDROBROMIDE - HYOSCINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.6 Drugs used in nausea and vertigo", "Hyoscine", "HYOSCINE HYDROBROMIDE"], "cautions": "Cautions\u00a0section 1.2; also epilepsy", "side-effects": "Side-effects\u00a0section 1.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200878.htm", "doses": ["Motion sickness, by mouth, adult and child over\r\n10 years, 150\u2013300\u00a0micrograms up to 30 minutes before start of journey\r\nrepeated every 6 hours if required; max. 900\u00a0micrograms daily; child 3\u20134 years 75\u00a0micrograms up to 30 minutes before\r\nstart of journey repeated after 6 hours if required, max. 150\u00a0micrograms\r\ndaily; 4\u201310 years 75\u2013150\u00a0micrograms up to 30 minutes before start\r\nof journey repeated every 6 hours if required; max. 450\u00a0micrograms\r\ndaily", "Hypersalivation associated with clozapine therapy [unlicensed\r\nindication], by mouth, 300\u00a0micrograms up to 3 times\r\ndaily; max. 900\u00a0micrograms daily; child under 18 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0section 15.1.3"}, {"indications": "Indications\u00a0symptomatic relief of gastro-intestinal or genito-urinary disorders\r\ncharacterised by smooth muscle spasm; bowel colic and excessive respiratory\r\nsecretions (see Bowel Colic and Excessive\r\nRespiratory Secretions)", "name": "HYOSCINE BUTYLBROMIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.2 Antispasmodics and other drugs altering gut motility", "Antimuscarinics", "HYOSCINE BUTYLBROMIDE"], "cautions": "Cautions\u00a0\n(From Antimuscarinics: British National Formulary)\nCautions\u00a0Antimuscarinics should be used with caution in Down\u2019s syndrome, in children and in the elderly; they should also be used with caution in gastro-oesophageal reflux disease, diarrhoea, ulcerative colitis, autonomic neuropathy, acute myocardial infarction, hypertension, conditions characterised by tachycardia (including hyperthyroidism, cardiac insufficiency, cardiac surgery), pyrexia, and in individuals susceptible to angle-closure glaucoma. Interactions: Appendix 1 (antimuscarinics).", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2084.htm", "doses": ["By mouth (but poorly absorbed, see\r\nnotes above), smooth muscle spasm, 20\u00a0mg 4 times daily; child 6\u201312 years, 10\u00a0mg 3 times daily", "Irritable bowel syndrome, 10\u00a0mg 3 times daily, increased if\r\nrequired up to 20\u00a0mg 4 times daily", "By intramuscular or slow intravenous injection, acute spasm and spasm\r\nin diagnostic procedures, 20\u00a0mg repeated after 30 minutes if necessary\r\n(may be repeated more frequently in endoscopy), max. 100\u00a0mg daily; child 2\u201318 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk"}]